ERBB2 and neoplasm: Immunohistochemistry of the tumor confirmed the following: Glandular carcinoma: HER2 1+, estrogen receptor-negative, progesterone receptor (+,2%), and Ki-67 = 60%; Metaplastic carcinoma: HER2-negative, estrogen receptor-negative, progesterone receptor-negative, and Ki-67 = 40%.